Hologic, Inc. (NASDAQ:HOLX)‘s stock had its “buy” rating restated by analysts at Piper Jaffray Companies in a research note issued to investors on Friday. They currently have a $51.00 price objective on the medical equipment provider’s stock. Piper Jaffray Companies’ target price suggests a potential upside of 14.32% from the company’s current price.

HOLX has been the subject of a number of other reports. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “strong-buy” rating and set a $49.00 price objective for the company in a report on Tuesday, April 4th. Leerink Swann restated an “outperform” rating and issued a $52.00 price objective on shares of Hologic in a report on Thursday, March 30th. Canaccord Genuity restated a “buy” rating and issued a $53.00 price objective on shares of Hologic in a report on Tuesday, May 9th. Barclays PLC set a $50.00 target price on shares of Hologic and gave the stock a “buy” rating in a research note on Wednesday, April 5th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $47.00 target price on shares of Hologic in a research note on Sunday, May 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $47.77.

Hologic (NASDAQ:HOLX) opened at 44.61 on Friday. Hologic has a 12 month low of $35.15 and a 12 month high of $46.80. The firm has a 50-day moving average of $44.35 and a 200 day moving average of $42.22. The firm has a market capitalization of $12.49 billion, a PE ratio of 15.99 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, May 10th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.46 by $0.04. The firm had revenue of $715.40 million during the quarter, compared to analyst estimates of $685.24 million. Hologic had a net margin of 27.31% and a return on equity of 25.26%. The business’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business posted $0.47 EPS. Equities research analysts forecast that Hologic will post $2.01 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Hologic, Inc. (HOLX) Stock Rating Reaffirmed by Piper Jaffray Companies” was published by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally copied and republished in violation of U.S. and international copyright laws. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/07/17/hologic-inc-holx-stock-rating-reaffirmed-by-piper-jaffray-companies.html.

In other Hologic news, Director Sally Crawford sold 16,969 shares of the business’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $44.00, for a total transaction of $746,636.00. Following the transaction, the director now directly owns 157,305 shares of the company’s stock, valued at approximately $6,921,420. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Elaine Ullian sold 8,849 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $45.28, for a total transaction of $400,682.72. Following the transaction, the director now directly owns 23,810 shares in the company, valued at $1,078,116.80. The disclosure for this sale can be found here. Over the last three months, insiders have sold 107,240 shares of company stock worth $4,716,859. Insiders own 0.79% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. increased its position in shares of Hologic by 418.5% in the first quarter. Victory Capital Management Inc. now owns 4,050,824 shares of the medical equipment provider’s stock worth $172,363,000 after buying an additional 3,269,503 shares during the last quarter. American Century Companies Inc. increased its position in shares of Hologic by 229.4% in the first quarter. American Century Companies Inc. now owns 3,164,928 shares of the medical equipment provider’s stock worth $134,668,000 after buying an additional 2,204,085 shares during the last quarter. Bank of Montreal Can increased its position in shares of Hologic by 67.8% in the first quarter. Bank of Montreal Can now owns 3,206,769 shares of the medical equipment provider’s stock worth $136,448,000 after buying an additional 1,295,885 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in shares of Hologic by 123.2% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,446,445 shares of the medical equipment provider’s stock worth $58,032,000 after buying an additional 798,541 shares during the last quarter. Finally, Pictet Asset Management Ltd. increased its position in shares of Hologic by 69.4% in the first quarter. Pictet Asset Management Ltd. now owns 1,585,461 shares of the medical equipment provider’s stock worth $67,461,000 after buying an additional 649,632 shares during the last quarter. 94.04% of the stock is currently owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.